Cue Biopharma
76 hedge funds and large institutions have $35M invested in Cue Biopharma in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
61% less capital invested
Capital invested by funds: $89.2M → $35M (-$54.2M)
63% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 32
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
76
Holding in Top 10
–
Calls
$160K
Puts
$173K
Top Buyers
| 1 | +$1.2M | |
| 2 | +$993K | |
| 3 | +$590K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$477K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$436K |
Top Sellers
| 1 | -$5.33M | |
| 2 | -$3.86M | |
| 3 | -$1.42M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$659K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$623K |